Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Net Income: 2022-2025

Historic Net Income for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to -$54.9 million.

  • Centessa Pharmaceuticals' Net Income fell 28.96% to -$54.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.7 million, marking a year-over-year decrease of 50.50%. This contributed to the annual value of -$235.8 million for FY2024, which is 56.04% down from last year.
  • As of Q3 2025, Centessa Pharmaceuticals' Net Income stood at -$54.9 million, which was down 9.03% from -$50.3 million recorded in Q2 2025.
  • In the past 5 years, Centessa Pharmaceuticals' Net Income registered a high of -$24.9 million during Q2 2023, and its lowest value of -$111.3 million during Q4 2024.
  • For the 3-year period, Centessa Pharmaceuticals' Net Income averaged around -$47.1 million, with its median value being -$42.6 million (2024).
  • Per our database at Business Quant, Centessa Pharmaceuticals' Net Income surged by 61.51% in 2023 and then plummeted by 202.22% in 2024.
  • Over the past 4 years, Centessa Pharmaceuticals' Net Income (Quarterly) stood at -$43.2 million in 2022, then increased by 14.68% to -$36.8 million in 2023, then crashed by 202.22% to -$111.3 million in 2024, then decreased by 28.96% to -$54.9 million in 2025.
  • Its Net Income stands at -$54.9 million for Q3 2025, versus -$50.3 million for Q2 2025 and -$26.1 million for Q1 2025.